Zoetis Faces Wall Street Reckoning as Guidance Cut Triggers Wave of Downgrades
Published on 08/10/2026 at 17:33 | Redaktion boerse-global.de
The sell-off in Zoetis shares shows no sign of letting up, with the animal health giant now trading within striking distance of its 52-week low after a punishing stretch that has erased roughly 16.4 percent of shareholder value since the company slashed its full-year outlook last month.
The stock slipped another 6.29 percent on Friday to EUR 62.84, leaving it just 0.87 percent above its lowest point of the past year. By Monday, the shares had inched up to EUR 62.24, a mere 0.42 percent above the fresh 52-week trough of EUR 61.98 marked that same day. Technical indicators point to deeply oversold conditions, with the relative strength index sitting at 37.7.
A cascade of analyst revisions
The downgrade cycle has been swift and unforgiving. UBS moved its rating on the stock to "Neutral" on Friday, trimming its price target from $99 to $85. That same day, Piper Sandler cut its target from $90 to $80. A day earlier, William Blair had already stepped to the sidelines, shifting from "Outperform" to "Market Perform," citing worse-than-expected declines in the dermatology franchise and continued share losses for the blockbuster parasiticide Simparica Trio.
The analyst community's growing unease stems from a guidance reset that landed harder than most had anticipated. On Thursday, Zoetis slashed its 2026 revenue forecast to a range of $9.12 billion to $9.32 billion, down from the previous $9.68 billion to $9.96 billion. Adjusted diluted earnings per share are now expected to land between $6.15 and $6.25, a sharp cut from the earlier $6.85 to $7.00 projection. Management has indicated the revised outlook reflects sales trends through July, which have yet to show any sign of market stabilization. The low end of the range even assumes further deterioration in dermatology and parasite-control categories.
The numbers behind the caution
The second-quarter results that triggered the reset paint a sobering picture. Revenue came in at $2.5 billion — flat on a reported basis but down 1 percent organically. Adjusted net income reached $781 million, or $1.87 per diluted share. The trouble is concentrated in the company's home market, where US revenue tumbled 7 percent, dragged down by an 11 percent collapse in the companion animal segment. Generic competition for Cerenia and Convenia, along with softening sales of the osteoarthritis drug Librela, weighed heavily on the quarter.
Should investors sell immediately? Or is it worth buying Zoetis?
CEO Kristin Peck attributed the weakness to fewer veterinary clinic visits and increasingly price-sensitive pet owners, which have dampened demand and intensified competition in key categories. Former CFO Wetteny Joseph added that sales trends through July had not indicated any market stabilization.
Not everything is broken. The livestock business posted 23 percent growth during the quarter, and international revenue advanced 6 percent, fueled by strong demand in emerging markets and continental Europe. The diagnostics franchise, including products like Vetscan Imagyst, delivered double-digit growth. Yet these bright spots have done little to offset concerns about the core US pet-care business.
Leadership transition adds another layer of uncertainty
Amid the operational turmoil, Zoetis is also reshuffling its executive ranks. James "Jay" Saccaro, formerly of GE HealthCare, steps in on August 17 as both Chief Financial Officer and Chief Operating Officer — a newly created dual role. Outgoing CFO Wetteny Joseph transitions to an advisory position the same day and will remain available to management through early 2027. The company also promoted Abhay Nayak to Executive Vice President and President of U.S. Commercial Operations.
The timing of the leadership change, coming squarely in the middle of a guidance crisis, gives investors another variable to weigh as the new management team must stabilize the struggling US companion animal franchise.
Capital returns continue despite the pressure
Zoetis has not wavered on returning cash to shareholders. The company repurchased more than $550 million worth of its own stock in the second quarter — 6,210,847 shares in total — bringing year-to-date capital returns through dividends and buybacks to $1.6 billion. The next quarterly dividend of $0.53 per share will be paid on September 1 to shareholders of record as of July 20.
On the product front, there were modest advances in July. Commercial sales of Portela, a monoclonal antibody for osteoarthritis pain in cats requiring administration only once every three months, launched in Canada and the European Union on July 22. The UK veterinary regulator VMD had approved the product on July 30. Such regulatory wins offer long-term potential, though they do little to relieve the near-term pressure from weak US demand.
Wall Street remains divided on the stock's prospects. JPMorgan's Chris Schott trimmed his target from $130 to $115 on Friday but held firm with an Overweight rating. UBS's Andrea Alfonso, meanwhile, lowered her target from $85 to $80 while maintaining Neutral. The breadth of the downgrades suggests the market is treating Zoetis's problems as structural rather than temporary — a view that will be tested in the coming quarters as the new leadership team charts a path forward.
Ad
Zoetis Stock: New Analysis - 10 August
Fresh Zoetis information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
